Our main conclusion is that the majority of patients with symptomatic GATA2 deficiency will need allo-HSCT, and a close surveillance of these patients is important to find the “optimal window” for allo-HSCT. The gene discussed is GATA2; the disease is hyperinsulinemic hypoglycemia, familial, 4.